Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C53H87NO19 |
| Molecular Weight | 1042.2532 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 21 / 21 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H]1OC(=O)C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@@H]1CO[C@@H]4O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]4OC
InChI
InChIKey=KCJJINQANFZSAM-HZDSEHBESA-N
InChI=1S/C53H87NO19/c1-16-38-36(26-65-52-49(64-15)48(63-14)44(60)31(7)67-52)22-28(4)17-18-37(57)29(5)23-35(19-20-55)46(30(6)39(69-34(10)56)24-41(59)70-38)73-51-45(61)43(54(12)13)47(32(8)68-51)72-42-25-53(11,62)50(33(9)66-42)71-40(58)21-27(2)3/h17-18,20,22,27,29-33,35-36,38-39,42-52,60-62H,16,19,21,23-26H2,1-15H3/b18-17+,28-22+/t29-,30+,31-,32-,33+,35+,36-,38-,39-,42+,43-,44-,45-,46-,47-,48-,49-,50+,51+,52-,53-/m1/s1
DescriptionSources: http://www.ecoanimalhealth.com/us/US04PIM-6A5%20Aivlosin%20Water%20soluble%20granules%20Pack%20Insert%20-%20USA%20-%20Pigs.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26392896https://www.ema.europa.eu/en/documents/product-information/aivlosin-epar-product-information_en.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19767637 | https://www.ncbi.nlm.nih.gov/pubmed/25185108 | https://www.ncbi.nlm.nih.gov/pubmed/29696149
Sources: http://www.ecoanimalhealth.com/us/US04PIM-6A5%20Aivlosin%20Water%20soluble%20granules%20Pack%20Insert%20-%20USA%20-%20Pigs.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26392896https://www.ema.europa.eu/en/documents/product-information/aivlosin-epar-product-information_en.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19767637 | https://www.ncbi.nlm.nih.gov/pubmed/25185108 | https://www.ncbi.nlm.nih.gov/pubmed/29696149
Tylvalosin tartrate is a third-generation macrolide antibiotic that has antibacterial activity against Gram-positive, some Gram-negative organisms and mycoplasma. Tylvalosin interferes with protein synthesis by reversibly binding to the 50S ribosome subunit. Tylvalosin binds to the donor site and prevents the translocation necessary for keeping the peptide chain growing. Its effect is essentially confined to rapidly dividing organisms. Tylvalosin tartrate is the active ingredient of Aivlosin -- a modern macrolide that has shown its effectiveness in the control of porcine proliferative enteropathy, EP and swine dysentery.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | AIVLOSIN Approved UseControl of porcine proliferative enteropathy (PPE)
associated with Lawsonia intracellularis infection in
groups of swine in buildings experiencing an outbreak
of PPE. Launch Date2012 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antibiotic susceptibility profiles of Mycoplasma sp. 1220 strains isolated from geese in Hungary. | 2016-08-19 |
|
| Antimicrobial susceptibility of Brachyspira hyodysenteriae in Switzerland. | 2016-06 |
|
| Use of tylvalosin in the control of porcine enzootic pneumonia. | 2015 |
|
| In vitro activity of tylvalosin against Spanish field strains of Mycoplasma hyopneumoniae. | 2014-11-29 |
Patents
Sample Use Guides
Control of porcine proliferative enteropathy: 50 ppm tylvalosin in drinking water for five consecutive
days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27543140
Tylvalosin (MIC50 0.5 ug/ml) was found to be the most effective drug against M. sp. 1220.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 520.2645
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
||
|
WHO-VATC |
QJ01FA92
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
||
|
CFR |
21 CFR 558.633
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
AIVLOSIN [AUTHORISED]
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
||
|
CFR |
21 CFR 556.748
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
AIVLOSIN [AUTHORISED]
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
AIVLOSIN [AUTHORISED]
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
AIVLOSIN [AUTHORISED]
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
||
|
NCI_THESAURUS |
C254
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9T02S42WQO
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
6441094
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
264-132-2
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
8533
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
1368469
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID901016510
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
9T02S42WQO
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
DB11554
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103834
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
UU-49
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
63409-12-1
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
300000023783
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
C545430
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
C152787
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY | |||
|
m11759
Created by
admin on Mon Mar 31 18:26:51 GMT 2025 , Edited by admin on Mon Mar 31 18:26:51 GMT 2025
|
PRIMARY |
ACTIVE MOIETY